Phaseline

Targets › IFIH1

IFIH1 (Interferon-induced helicase C domain-containing protein 1): drug programs, companies and trials

1 program from 1 company in 3 trials: 3 Phase 1; Oncology; next expected readout Aug 2027.

Innate immune receptor which acts as a cytoplasmic sensor of viral nucleic acids and plays a major role in sensing viral infection and in the activation of a cascade of antiviral responses including the induction of type I interferons and pro-inflammatory cytokines. Its ligands include mRNA lacking 2'-O-methylation at their 5' cap and long double-stranded RNAs (>1 kb in length). (UniProt, Q9BYX4)

Open in Phaseline: the race on IFIH1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Seqker BiosciencesPoly-ICLC (Hiltonol)
TLR3 and RIG-I-like receptor agonist; immune adjuvant
IFIH1, DDX58Phase 1Solid Tumors; Follicular Lymphoma; Lymphocytic LeukemiaAug 2027

Conditions

Solid Tumors (1) Follicular Lymphoma (1) Lymphocytic Leukemia (1)

Modalities

other (1)

Companies

Seqker Biosciences (1)

Related targets

DDX58 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.